ID   YSCCC-G100
AC   CVCL_QZ47
DR   Cell_Model_Passport; SIDM01929
DR   Wikidata; Q54995522
RX   PubMed=21451941;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI:175901; Gemcitabine (Gemzar).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C4436; Cholangiocarcinoma
DI   ORDO; Orphanet_70567; Cholangiocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3629 ! YSCCC
SX   Female
AG   70Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 29-06-23; Version: 7
//
RX   PubMed=21451941; DOI=10.1007/s00534-011-0376-7;
RA   Sato J., Kimura T., Saito T., Anazawa T., Kenjo A., Sato Y.,
RA   Tsuchiya T., Gotoh M.;
RT   "Gene expression analysis for predicting gemcitabine resistance in
RT   human cholangiocarcinoma.";
RL   J. Hepatobiliary Pancreat. Sci. 18:700-711(2011).
//